Extended follow-up following “full-metal jacket” percutaneous coronary interventions with drug-eluting stents

2014 ◽  
Vol 84 (7) ◽  
pp. 1042-1050 ◽  
Author(s):  
Sandeep Basavarajaiah ◽  
Toru Naganuma ◽  
Azeem Latib ◽  
Tasuku Hasegawa ◽  
Andrew Sharp ◽  
...  
Keyword(s):  
Drug Eluting Stents ◽  
Percutaneous Coronary Interventions ◽  
Coronary Interventions ◽  
Percutaneous Coronary ◽  
Drug Eluting ◽  
Full Metal Jacket

An insight into the current use of drug eluting stents in acute and elective percutaneous coronary interventions in Europe. A report on the EuroPCI Survey

10.4244/a78 ◽  
2008 ◽  
Vol 3 (4) ◽  
pp. 429-441 ◽  
Author(s):  
Steve Ramcharitar ◽  
Matthias Hochadel ◽  
Anne Gaster ◽  
Yoshinobu Onuma ◽  
Anselm Gitt ◽  
...  
Keyword(s):  
Drug Eluting Stents ◽  
Percutaneous Coronary Interventions ◽  
Coronary Interventions ◽  
Percutaneous Coronary ◽  
Drug Eluting ◽  
Insight Into

Comparison of Minimally Invasive Direct Coronary Artery Bypass Surgery with Implantation of Drug-Eluting Stents in Patients with Left Anterior Descending Coronary Artery Disease

2009 ◽  
Vol 4 (6) ◽  
pp. 340-344 ◽  
Author(s):  
Pierre Yves Etienne ◽  
David Glineur ◽  
Spiridon Papadatos ◽  
Gregory Kalscheuer ◽  
Yves Mairy ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Bypass Surgery ◽  
Artery Bypass ◽  
Drug Eluting Stents ◽  
Percutaneous Coronary Interventions ◽  
Percutaneous Coronary ◽  
Drug Eluting ◽  
Artery Disease

Objective Bypass surgery and percutaneous coronary interventions improve the clinical status of patients with left anterior descending coronary artery disease. However, these techniques differ in invasiveness and in the need for subsequent reinterventions. The development of minimally invasive direct coronary artery bypass (MIDCAB) surgery and of drug-eluting stents (DES) offers perspectives to close this gap. Methods We compared the long-term clinical outcome of 308 patients after revascularization for isolated left anterior descending coronary artery disease. One hundred fifty-four patients were treated with MIDCAB and 154 with percutaneous coronary interventions and DES implantation. Results Both groups were similar in age (63 ± 13 and 62 ± 10 years), Euroscore (3.3 ± 2.8 and 3.4 ± 2.6), and mean duration of follow-up (30 ± 17 and 24 ± 10 months). Two-year survival was similar after MIDCAB and after DES (97.4% and 94.8%). During follow-up, four patients (2.6%) of the MIDCAB group and 21 patients (13.6%) of the DES group needed subsequent revascularization of the target vessel (P = 0.001). Revascularization of a nontarget vessel was needed in 11 patients (7%) of the MIDCAB group and in 17 patients (11%) of the DES group (NS). Neurologic complications included two transient ischemic accidents and two strokes in the MIDCAB group but three fatal cerebral hemorrhages and one stroke in the DES group. Major adverse coronary and cerebrovascular events rates were 14% in the MIDCAB and 31% in the DES group. Conclusions MIDCAB and DES implantation showed similar rates of mortality but a higher reintervention rate after DES. Anticoagulation implications remain critical for the future of DES.

Sign in / Sign up

Export Citation Format

Share Document